Nabriva Therapeutics plc NBRV was a big mover last session, as the company saw its shares rise more than 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $0.54 –$1.14 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen three positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Nabriva Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Nabriva Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Nabriva Therapeutics plc Price
Nabriva Therapeutics plc price | Nabriva Therapeutics plc Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Akcea Therapeutics, Inc. AKCA, which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Nabriva Therapeutics AG (NBRV) : Free Stock Analysis Report
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research